The clinical course and outcome of COVID-19 are highly variable, ranging from
asymptomatic infections to severe disease and death. Understanding the risk factors of …

With the advent of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
pandemic, several vaccines have been developed to mitigate its spread and prevent …

The waning efficacy of SARS-CoV-2 vaccines, combined with the continued emergence of
variants resistant to vaccine-induced immunity, has reignited debate over the need for …

We retrospectively compared the long-term evolution of IgG anti-spike (S) and anti-
nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS …

Three COVID-19 vaccines have received FDA-authorization and are in use in the United
States, but there is limited head-to-head data on the durability of the immune response …

Background Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus
disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC …

Aim: To provide a comprehensive understanding of the varying effects of SARS-CoV-2
infection based on sex. Methods: A PubMed search of 470 primary articles was performed …

Limited data are available on the short‐to midterm levels of antibodies to the CoronaVac
vaccine and quantitative change in humoral response after homologous or heterologous …

Background Vaccines for coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) are being promoted worldwide. In this …

Background Little is known about vaccine efficacy and sustainability among people with HIV
(PWH). We estimated humoral and cellular immune responses postvaccination with …